Aadi Bioscience, INC Form 4 insider transactions

Whitehawk Therapeutics, Inc. reports the grant of a significant stock option to Chief Medical Officer Margaret Dugan.

Bryan Ball, Chief Technical Operations Officer at Whitehawk Therapeutics, reported significant equity transactions including the acquisition of restricted stock units and stock options.

Scott M. Giacobello, Chief Financial Officer of Whitehawk Therapeutics, Inc., reported significant stock transactions including the acquisition of restricted stock units and stock options.

Whitehawk Therapeutics CEO David James Lennon reported transactions involving company stock, including the acquisition of restricted stock units and stock options, and the sale of shares to cover tax obligations.

Whitehawk Therapeutics' Chief Medical Officer, Margaret Dugan, was granted 650,000 stock options and 55,309 Restricted Stock Units, aligning her incentives with shareholder value.

Whitehawk Therapeutics, Inc. Director and 10% owner, Zhao Baiteng, was granted 40,006 stock options with an exercise price of $2.04, vesting by June 2026.

Whitehawk Therapeutics, Inc. Director Neil Desai was granted 40,006 stock options with an exercise price of $2.04, vesting over one year or by the next annual meeting, as disclosed in a recent SEC Form 4 filing.

Mohammad Hirmand, a Director at Whitehawk Therapeutics, Inc., was granted 40,006 stock options with an exercise price of $2.04, aligning his interests with the company's long-term performance.

Whitehawk Therapeutics, Inc. Director and 10% Owner Richard E. Maroun was granted 40,006 stock options with an exercise price of $2.04, vesting over one year or prior to the next annual meeting.

Whitehawk Therapeutics, Inc. Director Emma Reeve was granted 40,006 stock options with an exercise price of $2.04, vesting over one year or prior to the next annual meeting.

Whitehawk Therapeutics, Inc. director Caley Castelein was granted 40,006 stock options with an exercise price of $2.04, vesting over one year or prior to the next annual meeting.

Anupam Dalal, a Director and 10% owner of Whitehawk Therapeutics, Inc., was granted 40,006 stock options with an exercise price of $2.04, vesting over one year or prior to the next annual meeting.

A recent SEC Form 4 filing reveals that Behzad Aghazadeh, a director and 10% owner of Whitehawk Therapeutics, Inc., was granted 40,006 stock options with an exercise price of $2.04, vesting over one year or until the next annual meeting.

Bryan Ball, Chief Technical Operations Officer and SVP of Manufacturing Operations at Whitehawk Therapeutics, acquired stock options and restricted stock units on April 1, 2025.

Scott M. Giacobello, CFO of Whitehawk Therapeutics, reports the acquisition of stock options and restricted stock units (RSUs) as part of his compensation.

Whitehawk Therapeutics CEO David James Lennon was granted stock options and restricted stock units on April 1, 2025, according to a Form 4 filing.

Director Anupam Dalal reports acquiring 1,561,000 shares of Aadi Bioscience, Inc. common stock at $2.4 per share on March 4, 2025.

Director Caley Castelein reports acquiring 1,666,000 shares of Aadi Bioscience, Inc. common stock on March 4, 2025, at a price of $2.4 per share.

Director Zhao Baiteng reports acquisition of 1,250,000 shares of Aadi Bioscience common stock at $2.4 per share on March 4, 2025.

David Dornan, Chief Scientific Officer of Aadi Bioscience, Inc., reports the acquisition of stock options.

Bryan Ball, Chief Technical Operations Officer and SVP, Manufacturing Operations at Aadi Bioscience, reports acquisition and disposal of company stock and stock units.

Avoro Capital Advisors, Avoro Ventures, and Behzad Aghazadeh acquired pre-funded warrants for Aadi Bioscience common stock in a private placement, subject to a 19.99% ownership blocker.

Scott Giacobello, CFO of Aadi Bioscience, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

CEO David James Lennon of Aadi Bioscience, Inc. reports the acquisition and disposal of company stock and restricted stock units.

Aadi Bioscience director, Zhao Baiteng, acquired 61,192 stock options on December 19, 2024, which vest over three years.

Aadi Bioscience CEO David Lennon exercised stock options and sold a portion of the acquired shares to cover tax obligations.

Neil Desai, Executive Chairman of Aadi Bioscience, Inc., sold 40,000 shares of common stock on September 3, 2024, at an average price of $1.7079.

Neil Desai, Executive Chairman of Aadi Bioscience, sold shares of common stock between August 1 and August 5, 2024, according to a Form 4 filing with the SEC.

Neil Desai, Executive Chairman of Aadi Bioscience, sold shares of the company's common stock on July 1st and 2nd, 2024, according to a Form 4 filing with the SEC.

Behzad Aghazadeh, along with Avoro Capital Advisors and Avoro Ventures, reports the acquisition of stock options in Aadi Bioscience, Inc.